Inhibition of Akt pathways in the treatment of prostate cancer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

Original languageEnglish (US)
Pages (from-to)331-339
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume10
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

Celecoxib
Genistein
Protein-Serine-Threonine Kinases
Biological Factors
Prostatic Neoplasms
Research
Neoplasms
Therapeutics
perifosine
Clinical Studies

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{3685e25886644e44a8b5d2470a6782b5,
title = "Inhibition of Akt pathways in the treatment of prostate cancer",
abstract = "Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.",
author = "Nelson, {E. C.} and Evans, {Christopher P} and Philip Mack and {deVere White}, {Ralph W} and Lara, {Primo N}",
year = "2007",
month = "12",
doi = "10.1038/sj.pcan.4500974",
language = "English (US)",
volume = "10",
pages = "331--339",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Inhibition of Akt pathways in the treatment of prostate cancer

AU - Nelson, E. C.

AU - Evans, Christopher P

AU - Mack, Philip

AU - deVere White, Ralph W

AU - Lara, Primo N

PY - 2007/12

Y1 - 2007/12

N2 - Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

AB - Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

UR - http://www.scopus.com/inward/record.url?scp=36949028765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949028765&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500974

DO - 10.1038/sj.pcan.4500974

M3 - Article

VL - 10

SP - 331

EP - 339

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -